Quick summary: ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis .
ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
Cases of immune-mediated encephalitis and meningoencephalitis, some with fatal outcomes, have been reported in patients treated with ZINBRYTA. No cases have been reported in Canada.
What you should do
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.